Results 231 to 240 of about 555,245 (354)
Clinical Characteristics and Outcomes of Early‐Onset Versus Late‐Onset LGI1‐Antibody Encephalitis
ABSTRACT Background Leucine‐rich glioma‐inactivated 1 antibody (LGI1‐Ab) encephalitis predominantly affected older individuals, but has also been reported in younger patients. However, the demographic, clinical, and prognostic characteristics of early‐onset LGI1‐Ab encephalitis have yet to be systematically elucidated. This study aims to systematically
Yu Kong +7 more
wiley +1 more source
The homeobox transcription factor MNX1 regulates the expression of many non-MN-specific neuronal genes in motor neurons. [PDF]
Sun MA +9 more
europepmc +1 more source
Amine Modulation of Glutamate Responses From Pyloric Motor Neurons in Lobster Stomatogastric Ganglion [PDF]
Bruce R. Johnson +1 more
openalex +1 more source
RAB39B Related Parkinsonism in an Italian Family: A Unique Use of Advanced Therapies
ABSTRACT Parkinson's disease (PD) is a neurodegenerative disorder that may sometimes be caused by deleterious genetic variants. Among them, RAB39B polymorphisms are known as rare causes of early‐onset PD associated with intellectual disability (Waisman's syndrome).
Caterina Del Regno +13 more
wiley +1 more source
Mechanisms of Different Motor Neurons in the Occurrence of Spasticity After Spinal Cord Injury: A Narrative Review. [PDF]
Gong H +6 more
europepmc +1 more source
Amyotrophic Lateral Sclerosis Prevalence Projection in 2040: A Less Rare Disease
ABSTRACT Objective To project ALS prevalence across multiple countries through 2040, accounting for both population aging and increased survival. Methods Data from the Piemonte and Valle d'Aosta ALS register (PARALS) was used to estimate the trends in incidence and prevalence from 2005 to 2019. Survival trends over this period were also assessed.
Rosario Vasta +18 more
wiley +1 more source
MBNL deficiency in motor neurons disrupts neuromuscular junction maintenance and gait coordination. [PDF]
Frison-Roche C +13 more
europepmc +1 more source
ABSTRACT Background There is growing recognition of the potential of plasma proteomics for Alzheimer's Disease (AD) risk assessment and disease characterization. However, differences between proteomics platforms introduce uncertainties regarding cross‐platform applicability.
Manyue Hu +9 more
wiley +1 more source

